We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes.
The cost-effectiveness of nilotinib compared to dasatinib, in patients resistant to imatinib has not been demonstrated.
Lapatinib could be considered cost-effective inIreland. However in view of the uncertainty surrounding the ICER, we (NCPE) suggest conditional reimbursement under the High Tech Drugs scheme.
The cost-effectiveness of Grazax® remains to be established and this product cannot be recommended as value for money at this point in time.
Cost effectiveness analysis of a universal infant hepatitis B vaccination programme in Ireland
Cost effectiveness analysis of a universal infant pneumococcal conjugate vaccination programme in Ireland.
The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.
The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.